Working with TipRanks
Follow Us
Stock Ideas
Daily Updates
Calendars
Education
About Us
Working with TipRanks
Follow Us
Aptose Biosciences (APTO)
NASDAQ:APTO
Aptose Biosciences (APTO) Stock Price & Analysis
1,077 Followers
APTO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.36 - $1.00
Previous Close$0.43
Volume886.43K
Average Volume (3M)225.87K
Market Cap
C$54.32M
Enterprise Value-$5.20M
Total Cash (Recent Filing)$46.96M
Total Debt (Recent Filing)$1.30M
Price to Earnings (P/E)-0.9
Beta0.70
Next Earnings
Aug 08, 2023EPS Estimate
-$0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.48
Shares Outstanding92,367,275
10 Day Avg. Volume435,282
30 Day Avg. Volume225,872
Standard Deviation0.25
R-Squared0.11
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)1.40
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.16
Forecast
1Y Price Target
$7.00Price Target Upside1540.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Aptose Biosciences News
Press ReleasesAptose Enters into $25 Million Committed Equity Facility
Press ReleasesAptose Reports Results for the First Quarter 2023
Pre-EarningsIs APTO a Buy, Before Earnings?
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Insights
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
APTO FAQ
What was Aptose Biosciences’s price range in the past 12 months?
Aptose Biosciences lowest stock price was $0.36 and its highest was $1.00 in the past 12 months.
What is Aptose Biosciences’s market cap?
Currently, no data Available
When is Aptose Biosciences’s upcoming earnings report date?
Aptose Biosciences’s upcoming earnings report date is Aug 08, 2023 which is in 64 days.
How were Aptose Biosciences’s earnings last quarter?
Aptose Biosciences released its earnings results on May 08, 2023. The company reported -$0.15 earnings per share for the quarter, missing the consensus estimate of -$0.117 by -$0.033.
Is Aptose Biosciences overvalued?
According to Wall Street analysts Aptose Biosciences’s price is currently Undervalued.
Does Aptose Biosciences pay dividends?
Aptose Biosciences does not currently pay dividends.
What is Aptose Biosciences’s EPS estimate?
Aptose Biosciences’s EPS estimate is -$0.14.
How many shares outstanding does Aptose Biosciences have?
Aptose Biosciences has 93,653,660 shares outstanding.
What happened to Aptose Biosciences’s price movement after its last earnings report?
Aptose Biosciences reported an EPS of -$0.15 in its last earnings report, missing expectations of -$0.117. Following the earnings report the stock price went down -3.774%.
Which hedge fund is a major shareholder of Aptose Biosciences?
Among the largest hedge funds holding Aptose Biosciences’s share is Carlson Capital LP. It holds Aptose Biosciences’s shares valued at 1M.
---
Aptose Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.00 (1540.88% Upside)
$7.00 (1540.88% Upside)
Blogger Sentiment
Neutral
APTO Sentiment 50%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 310.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 16.9%
Last 30 Days ▲ 16.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-57.42%
12-Months-Change
Fundamentals
Return on Equity
-96.45%
Trailing 12-Months
Asset Growth
-45.83%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Aptose Biosciences
Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG-806 a non-covalent small molecule therapeutic agent. The company was founded on September 5, 1986 and is headquartered in Toronto, Canada.
---
---